Loading Chart Rhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
COO • Stock • Health Care / Health Care Supplies
Executive Summary
Supportive setup. COO has a positive source-backed read, but the next articles still need to confirm the same story.
Price Rhythm Chart
Chart Rhythms is showing the current market read with live or fallback quote data.
Strategy Scorecard
Daily Setup
Supportive
Swing Setup
Building
Long-Term Setup
Constructive
Confidence
Medium
Risk Level
Low
Today Strategy
Today’s setup is supportive. The latest articles are giving the stock a positive tone, with growth expectations, earnings expectations, and guidance watch acting as the main driver. The daily read stays useful only if fresh headlines keep supporting the same idea.
Swing Strategy
For the next few weeks to months, the swing setup depends on repetition. If growth expectations, earnings expectations, and guidance watch keeps appearing across new articles, the read strengthens. If the theme fades or risk language rises, the setup weakens.
Long-Term Strategy
For the long-term view, the system is watching whether Cooper Companies (The)'s bigger story remains durable. The current narrative is connected to growth expectations, earnings expectations, and guidance watch, but the long-term read still depends on valuation, competition, margins, execution, and whether future sources continue supporting the thesis.
These are the latest sources connected to this strategy report.
Source: Yahoo • Published: 2026-06-08
Evaluate The Cooper Companies' (COO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
View original source →Source: Yahoo • Published: 2026-06-06
Earlier this week, The Cooper Companies reported second-quarter 2026 results showing record sales of US$1,081.5 million but a net loss of US$77.9 million, largely due to a US$271.6 million litigation charge tied to a 2023 CooperSurgical product recall. The company paired this with updated full-year 2026 revenue guidance of about US$4.29–US$4.32 billion, confirmation of stronger non‑GAAP earnings, and completion of a long-running share repurchase program totaling over US$1.14 billion,...
View original source →Source: Yahoo • Published: 2026-06-05
The medical device maker gave an update on its troubled CooperSurgical business segment that was music to Wall Street’s ears.
Help improve this analysis
This feedback is saved locally for the MVP. Later, Chart Rhythms can use this feedback to improve the strategy engine.
Important:
Chart Rhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
Source: Yahoo • Published: 2026-06-05
Cooper Companies beats Q2 EPS and sales estimates as CooperVision and CooperSurgical hit record revenues, even with a GAAP loss from recall litigation.
View original source →Source: Benzinga • Published: 2026-06-05
JP Morgan analyst Robbie Marcus maintains Cooper Companies (NASDAQ:COO) with a Neutral and lowers the price target from $80 to $71.
View original source →Source: Benzinga • Published: 2026-06-05
Stifel analyst Jonathan Block maintains Cooper Companies (NASDAQ:COO) with a Buy and lowers the price target from $95 to $85.
View original source →Source: Benzinga • Published: 2026-06-05
Wells Fargo analyst Larry Biegelsen maintains Cooper Companies (NASDAQ:COO) with a Equal-Weight and lowers the price target from $82 to $66.
View original source →Source: Benzinga • Published: 2026-06-05
Needham analyst David Saxon maintains Cooper Companies (NASDAQ:COO) with a Buy and lowers the price target from $101 to $86.
View original source →